In this study, we assessed the effect of CCL22 on the expression of M2a marker CD206 by flowcytometry and revealed that CCL22 could be a therapeutic target for cervical cancer, which might be due to its role in regulating macrophage polarization. The gene discussed is MRC1; the disease is cervical carcinoma.